Risdiplam-hydroxylate-d3
Risdiplam-hydroxylate-d3 is a Risdiplam-hydroxylate tritium substitute. Risdiplam (RG7916) is an orally administered, centrally and peripherally distributed SMN2 pre-mRNA splicing modifier that increases survival motor neuron (SMN) protein levels[1].
Product Specifications
UNSPSC
12352005
Target
DNA/RNA Synthesis; Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Cell Cycle/DNA Damage; Others
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Solubility
10 mM in DMSO
Smiles
O=C1C=C(C2=NN3C=C(C)N=C3C(C([2H])([2H])[2H])=C2)N=C4C=CC(N5CCN(C6(CC6)C5)O)=CN14
Molecular Formula
C22H20D3N7O2
Molecular Weight
420.48
References & Citations
[1]Ratni H, et al. Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 (SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA) . J Med Chem. 2018 Aug 9;61 (15) :6501-6517.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog